CoChat

The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia

Open access
Chen, Fangzhe, Wang, Weifeng, Ding, Hongyan, Yang, Qi, Dong, Qiang, Cui, Mei · 2016 · Journal of Neuroinflammation

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

BACKGROUND: As the number of patients with cardioembolic ischemic stroke is predicted to be double by 2030, increased burden of warfarin-associated hemorrhagic transformation (HT) after cerebral ischemia is an expected consequence. However, thus far, no effective treatment strategy is available for HT prevention in routine clinical practice. While the glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 (Ex-4) is known to protect against oxidative stress and neuronal cell death caused by ischemic brain damage, its effect on preventing warfarin-associated HT after cerebral ischemia is yet unknown. Therefore, we hypothesized that Ex-4 would stabilize the blood-brain barrier (BBB) and suppress neuroinflammation through PI3K-Akt-induced inhibition of glycogen synthase kinase-3β (GSK-3β) after warfarin-associated HT post-cerebral ischemia. METHODS: We used male C57BL/6 mice for all experiments. A 5-mg warfarin sodium tablet was dissolved in animals' drinking water (effective warfarin uptake 0.04 mg (2 mg/kg) per mouse). The mice were fed for 0, 6, 12, and 24 h with ad libitum access to the treated water. To study the effects of Ex-4, temporary middle cerebral artery occlusion (MCAO) was performed. Then, either Ex-4 (10 mg/kg) or saline was injected through the tail vein, and in the Ex-4 + wortmannin group, PI3K inhibitor wortmannin was intravenously injected, after reperfusion. The infarct volume, neurological deficits, and integrity of the BBB were assessed 72 h post MCAO. One- or two-way ANOVA was used to test the difference between means followed by Newman-Keuls post hoc testing for pair-wise comparison. RESULTS: We observed that Ex-4 ameliorated warfarin-associated HT and preserved the integrity of the BBB after cerebral ischemia through the PI3K/Akt/GSK-3β pathway. Furthermore, Ex-4 suppressed oxidative DNA damage and lipid peroxidation, attenuated pro-inflammatory cytokine expression levels, and suppressed microglial activation and neutrophil infiltration in warfarin-associated HT post-cerebral ischemia. However, these effects were totally abolished in the mice treated with Ex-4 + the PI3K inhibitor-wortmannin. The PI3K/Akt-GSK-3β signaling pathway appeared to contribute to the protection afforded by Ex-4 in the warfarin-associated HT model. CONCLUSIONS: GLP-1 administration could reduce warfarin-associated HT in mice. This beneficial effect of GLP-1 is associated with attenuating neuroinflammation and BBB disruption by inactivating GSK-3β through the PI3K/Akt pathway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-016-0661-0

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Exendin-4 treatment reduced the stroke volume and improved neurological function after cerebral ischemia. a Prothrombin time-international normalized ratio values (PT-INR) in non-MCAO mice after 0, 6, 12, and 24 h of warfarin administration through drinking water. b Regional cerebral blood flow (rCBF) in both ischemic and reperfusion stages was recorded using laser Doppler cerebral blood flow. c Exendin-4 (Ex-4, 10 mg/kg) was injected through the tail vein immediately after reperfusion. The infarct volume was measured 72 h after middle cerebral artery occlusion (MCAO) using TTC straining. d Representative images of TTC straining showing the ischemic area and hemorrhage transformation. e, f Exendin-4 (Ex-4, 10 mg/kg) was injected through tail vein immediately after reperfusion. The neurological deficits were measured 72 h after MCAO, and assessment of motor function was analyzed on days 3 and 7 using rota rod after MCAO. Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) group
Fig. 1 Exendin-4 treatment reduced the stroke volume and improved neurological function after cerebral ischemia. a Prothrombin time-international normalized ratio values (PT-INR) in non-MCAO mice after 0, 6, 12, and 24 h of warfarin administration through drinking water. b Regional cerebral blood flow (rCBF) in both ischemic and reperfusion stages was recorded using laser Doppler cerebral blood flow. c Exendin-4 (Ex-4, 10 mg/kg) was injected through the tail vein immediately after reperfusion. The infarct volume was measured 72 h after middle cerebral artery occlusion (MCAO) using TTC straining. d Representative images of TTC straining showing the ischemic area and hemorrhage transformation. e, f Exendin-4 (Ex-4, 10 mg/kg) was injected through tail vein immediately after reperfusion. The neurological deficits were measured 72 h after MCAO, and assessment of motor function was analyzed on days 3 and 7 using rota rod after MCAO. Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) groupCC BY · PubMed Central
Fig. 2 Exendin-4 treatment reduced warfarin-associated HT after cerebral ischemia. a Brain hemoglobin levels were evaluated at 72 h after middle cerebral artery occlusion (MCAO). Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the MCAO+/Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) group. b Blood-brain barrier (BBB) integrity in MCAO mice were assessed after Evans blue staining. Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) group
Fig. 2 Exendin-4 treatment reduced warfarin-associated HT after cerebral ischemia. a Brain hemoglobin levels were evaluated at 72 h after middle cerebral artery occlusion (MCAO). Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the MCAO+/Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) group. b Blood-brain barrier (BBB) integrity in MCAO mice were assessed after Evans blue staining. Data are presented as mean ± SD and analyzed by two-way ANOVA. *P < 0.05 compared with the Ex-4(−) group, # P < 0.05 compared with the MCAO+/Ex-4(+) groupCC BY · PubMed Central
Fig. 3 Exendin-4 treatment preserved BBB integrity in warfarin-associated HT after cerebral ischemia. Western blot analysis of a, b p-GSK-3β/GSK-3β; c, d p-β-catenin/β-catenin; e, f claudin-3; and g, h claudin-5. Representative blots from six independent experiments with similar results are shown. (Sham: sham-operated group, Ctrl: MCAO group, W: warfarin-associated HT group, W + Ex-4: warfarin-associated HT pretreatment with Ex-4). Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 compared with warfarin-associated HT group
Fig. 3 Exendin-4 treatment preserved BBB integrity in warfarin-associated HT after cerebral ischemia. Western blot analysis of a, b p-GSK-3β/GSK-3β; c, d p-β-catenin/β-catenin; e, f claudin-3; and g, h claudin-5. Representative blots from six independent experiments with similar results are shown. (Sham: sham-operated group, Ctrl: MCAO group, W: warfarin-associated HT group, W + Ex-4: warfarin-associated HT pretreatment with Ex-4). Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 compared with warfarin-associated HT groupCC BY · PubMed Central
Fig. 4 Effect of Ex-4 on PI3K/Akt/GSK-3β pathway in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated either with Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus the PI3K inhibitor (wortmannin) (15 μL/kg) right after reperfusion. The expression levels of a, b p-Akt/Akt and c, d p-GSK-3β/GSK-3β were analyzed by immunoblotting. Representative blots from six independent experiments with similar results are shown. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 4 Effect of Ex-4 on PI3K/Akt/GSK-3β pathway in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated either with Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus the PI3K inhibitor (wortmannin) (15 μL/kg) right after reperfusion. The expression levels of a, b p-Akt/Akt and c, d p-GSK-3β/GSK-3β were analyzed by immunoblotting. Representative blots from six independent experiments with similar results are shown. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central
Fig. 5 Ex-4 alleviated warfarin-associated HT after cerebral ischemia through PI3K/Akt/GSK-3β pathway. Effects of GSK-3β siRNA and wortmannin on a brain hemoglobin level and b Evans blue extravasation were evaluated 72 h after MCAO. c, d The expression levels of p-β-catenin/β-catenin were also been detected by western blotting. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 5 Ex-4 alleviated warfarin-associated HT after cerebral ischemia through PI3K/Akt/GSK-3β pathway. Effects of GSK-3β siRNA and wortmannin on a brain hemoglobin level and b Evans blue extravasation were evaluated 72 h after MCAO. c, d The expression levels of p-β-catenin/β-catenin were also been detected by western blotting. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central
Fig. 6 Ex-4 preserved the BBB integrity after warfarin-associated HT through PI3K/Akt/GSK-3β pathway. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a claudin-3, b claudin-5, c ICAM-1, and d VCAM-1 were analyzed by western blotting. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 6 Ex-4 preserved the BBB integrity after warfarin-associated HT through PI3K/Akt/GSK-3β pathway. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a claudin-3, b claudin-5, c ICAM-1, and d VCAM-1 were analyzed by western blotting. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central
Fig. 7 Ex-4 suppressed oxidative DNA damage and lipid peroxidation in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a HHE and b 8-OHdG in the brain tissue were detected. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 7 Ex-4 suppressed oxidative DNA damage and lipid peroxidation in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a HHE and b 8-OHdG in the brain tissue were detected. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central
Fig. 8 Ex-4 attenuated pro-inflammatory cytokines in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a IKK-β and b NF-kB were analyzed by western blotting. The concentrations of pro-inflammatory cytokines c TNF-α and d IL-1β were detected by ELISA. Data are mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 8 Ex-4 attenuated pro-inflammatory cytokines in warfarin-associated HT after cerebral ischemia. Mice were intravenously treated with either Ex-4 (Ex-4, 10 mg/kg) or Ex-4 plus wortmannin (15 μL/kg) right after reperfusion. The expression levels of a IKK-β and b NF-kB were analyzed by western blotting. The concentrations of pro-inflammatory cytokines c TNF-α and d IL-1β were detected by ELISA. Data are mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central
Fig. 9 Ex-4 reduced Iba1+ microglial/macrophage cells and neutrophil infiltration in warfarin-associated HT after cerebral ischemia. Immunostaining of Iba1 was performed in the cortical and subcortical areas supplied by the middle cerebral artery. a Representative immunofluorescence images showed Iba1+ (green) and DAPI+ (blue) microglia/macrophages in the Ex-4-treated mice compared to the warfarin-associated HT group. Scale bar 100 μm. b Quantitative analysis of Iba1+ cells. The expression levels of Iba1 (c) and MPO (d) were detected by western blotting. e Representative images show microglial morphology in different groups. Scale bar 50 μm. f The number of activated microglia was expressed as a percentage of the total number of Iba1+ cells. g The cell body to cell size ratio of microglia provides additional information about microglial activation. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 group
Fig. 9 Ex-4 reduced Iba1+ microglial/macrophage cells and neutrophil infiltration in warfarin-associated HT after cerebral ischemia. Immunostaining of Iba1 was performed in the cortical and subcortical areas supplied by the middle cerebral artery. a Representative immunofluorescence images showed Iba1+ (green) and DAPI+ (blue) microglia/macrophages in the Ex-4-treated mice compared to the warfarin-associated HT group. Scale bar 100 μm. b Quantitative analysis of Iba1+ cells. The expression levels of Iba1 (c) and MPO (d) were detected by western blotting. e Representative images show microglial morphology in different groups. Scale bar 50 μm. f The number of activated microglia was expressed as a percentage of the total number of Iba1+ cells. g The cell body to cell size ratio of microglia provides additional information about microglial activation. Data are presented as mean ± SD from six independent experiments and analyzed by one-way ANOVA. *P < 0.05 vs. MCAO group; # P < 0.05 vs. MCAO + warfarin group; **P < 0.05 vs. MCAO + warfarin + Ex-4 groupCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 59 references

Cited by

See all 57

Metadata

Authors
Chen, F., Wang, W., Ding, H., Yang, Q., Dong, Q., & Cui, M.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Dong, Qiang
  • Cui, Mei
Venue
Journal of Neuroinflammation
Published
2016-08-26
Volume
13
Issue
1
Pages
204-204
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2514294108
Cited by
52
References
58
Citations by year
2026: 6 · 2025: 6 · 2024: 5 · 2023: 2 · 2022: 9 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 4 · 2017: 1
FWCI
3.74
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (81471173, 81271295, 81571109)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
exendin-4, warfarin, hemorrhagic transformation, cerebral ischemia, ischemic stroke, blood-brain barrier, PI3K/Akt/GSK-3β signaling, neuroinflammation, oxidative stress, microglial activation, neutrophil infiltration, inflammatory cytokines, wortmannin, GLP-1 receptor agonists, middle cerebral artery occlusion
MeSH terms
Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anticoagulants, Blood-Brain Barrier, Brain, Brain Ischemia, Disease Models, Animal, Gene Expression Regulation, Hemorrhage, Hypoglycemic Agents, Male, Mice, Inbred C57BL, Nervous System Diseases, Peptides, Venoms, Warfarin, Signal Transduction, Cytokines, Microglia, Infarction, Middle Cerebral Artery, Brain Infarction, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. https://app.cochat.ai/papers/10.1186/s12974-016-0661-0
The paper
Chen, F., Wang, W., Ding, H., Yang, Q., Dong, Q., & Cui, M. (2016). The glucagon-like peptide-1 receptor agonist exendin-4 ameliorates warfarin-associated hemorrhagic transformation after cerebral ischemia. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-016-0661-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.